Aerovate Therapeutics (AVTE) Competitors $2.53 0.00 (0.00%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AVTE vs. CMPS, FHTX, ACIU, AMLX, LFCR, ITOS, ELDN, URGN, RZLT, and AVIRShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include COMPASS Pathways (CMPS), Foghorn Therapeutics (FHTX), AC Immune (ACIU), Amylyx Pharmaceuticals (AMLX), Lifecore Biomedical (LFCR), iTeos Therapeutics (ITOS), Eledon Pharmaceuticals (ELDN), UroGen Pharma (URGN), Rezolute (RZLT), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry. Aerovate Therapeutics vs. COMPASS Pathways Foghorn Therapeutics AC Immune Amylyx Pharmaceuticals Lifecore Biomedical iTeos Therapeutics Eledon Pharmaceuticals UroGen Pharma Rezolute Atea Pharmaceuticals Aerovate Therapeutics (NASDAQ:AVTE) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, community ranking, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Which has stronger earnings & valuation, AVTE or CMPS? COMPASS Pathways is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAerovate TherapeuticsN/AN/A-$75.52M-$2.99-0.85COMPASS PathwaysN/AN/A-$118.46M-$2.20-1.80 Does the media refer more to AVTE or CMPS? In the previous week, Aerovate Therapeutics had 1 more articles in the media than COMPASS Pathways. MarketBeat recorded 3 mentions for Aerovate Therapeutics and 2 mentions for COMPASS Pathways. COMPASS Pathways' average media sentiment score of 1.53 beat Aerovate Therapeutics' score of 1.30 indicating that COMPASS Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aerovate Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive COMPASS Pathways 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is AVTE or CMPS more profitable? COMPASS Pathways' return on equity of -63.85% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aerovate TherapeuticsN/A -90.19% -77.47% COMPASS Pathways N/A -63.85%-51.97% Do analysts rate AVTE or CMPS? Aerovate Therapeutics presently has a consensus price target of $2.25, indicating a potential downside of 11.07%. COMPASS Pathways has a consensus price target of $33.60, indicating a potential upside of 746.35%. Given COMPASS Pathways' stronger consensus rating and higher probable upside, analysts plainly believe COMPASS Pathways is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00COMPASS Pathways 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer AVTE or CMPS? COMPASS Pathways received 41 more outperform votes than Aerovate Therapeutics when rated by MarketBeat users. Likewise, 80.00% of users gave COMPASS Pathways an outperform vote while only 54.29% of users gave Aerovate Therapeutics an outperform vote. CompanyUnderperformOutperformAerovate TherapeuticsOutperform Votes1954.29% Underperform Votes1645.71% COMPASS PathwaysOutperform Votes6080.00% Underperform Votes1520.00% Do institutionals and insiders believe in AVTE or CMPS? 46.2% of COMPASS Pathways shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by insiders. Comparatively, 4.3% of COMPASS Pathways shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, AVTE or CMPS? Aerovate Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.24, suggesting that its stock price is 124% more volatile than the S&P 500. SummaryCOMPASS Pathways beats Aerovate Therapeutics on 11 of the 15 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$73.05M$6.57B$5.10B$9.07BDividend YieldN/A2.97%4.90%4.21%P/E Ratio-0.8510.5591.0817.15Price / SalesN/A195.381,113.51116.81Price / CashN/A57.1642.2637.86Price / Book0.645.104.784.78Net Income-$75.52M$151.51M$119.77M$225.60M7 Day PerformanceN/A-2.12%-1.87%-1.23%1 Month Performance-3.07%-3.11%11.46%3.07%1 Year Performance-87.43%11.52%30.53%16.48% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate Therapeutics1.2561 of 5 stars$2.53flat$2.25-11.1%-86.4%$73.05MN/A-0.8551Short Interest ↓Positive NewsCMPSCOMPASS Pathways2.8367 of 5 stars$4.29+1.7%$33.60+683.2%-47.3%$293.53MN/A-1.92120Positive NewsFHTXFoghorn Therapeutics2.8871 of 5 stars$5.27-0.6%$16.00+203.6%-14.0%$292.98M$25.52M-2.63120Analyst ForecastAnalyst RevisionNews CoverageGap DownHigh Trading VolumeACIUAC Immune2.4761 of 5 stars$2.95flat$12.00+306.8%-33.8%$291.87M$16.48M-6.41140Positive NewsAMLXAmylyx Pharmaceuticals4.2412 of 5 stars$4.18+1.5%$7.33+75.4%-70.7%$286.53M$196.49M-1.08200Short Interest ↓News CoveragePositive NewsLFCRLifecore Biomedical3.558 of 5 stars$7.71+1.3%$10.00+29.7%+18.7%$283.94M$128.44M97.50690ITOSiTeos Therapeutics3.4996 of 5 stars$7.72+0.5%$25.25+227.1%-28.4%$282.04M$35M-2.4490Analyst ForecastELDNEledon Pharmaceuticals2.9286 of 5 stars$4.49+2.5%$16.00+256.3%+196.6%$268.23MN/A-2.3310Positive NewsHigh Trading VolumeURGNUroGen Pharma3.8718 of 5 stars$11.33-0.2%$43.70+285.7%-28.4%$265.69M$82.71M-3.60200RZLTRezolute3.1807 of 5 stars$4.56-0.7%$24.13+429.1%+387.8%$264.22MN/A-3.6140AVIRAtea Pharmaceuticals3.2604 of 5 stars$3.12+6.5%$6.88+120.5%+5.6%$263.53M$351.37M-1.5370High Trading Volume Related Companies and Tools Related Companies COMPASS Pathways Competitors Foghorn Therapeutics Competitors AC Immune Competitors Amylyx Pharmaceuticals Competitors Lifecore Biomedical Competitors iTeos Therapeutics Competitors Eledon Pharmaceuticals Competitors UroGen Pharma Competitors Rezolute Competitors Atea Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AVTE) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVTE Stock Alerts